Literature DB >> 27725576

T1 Shortening in the Cerebral Cortex after Multiple Administrations of Gadolinium-based Contrast Agents.

Zaw Aung Khant1, Toshinori Hirai, Yoshihito Kadota, Rie Masuda, Takanori Yano, Minako Azuma, Yukiko Suzuki, Kuniyuki Tashiro.   

Abstract

We report a 34-year-old male who manifested T1 shortening of the cerebral cortices after more than 86 contrast-enhanced MRI studies. We observed high-signal intensity (SI) on T1-weighted images (T1WIs) not only in the globus pallidus, dentate nucleus, and pulvinar of thalamus, but also in the cortices of the pre- and post-central gyri and around the calcarine sulcus. High SI in the cerebral cortices was not clearly demonstrated on T1WI scans performed 11 years earlier. The high SI we observed in these areas of the brain corresponded to areas with a normal iron-deposition predilection. Gadolinium deposition in the brain may be associated with the iron metabolism.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27725576      PMCID: PMC5600049          DOI: 10.2463/mrms.mp.2016-0054

Source DB:  PubMed          Journal:  Magn Reson Med Sci        ISSN: 1347-3182            Impact factor:   2.471


Introduction

Gadolinium (Gd) deposition in the brain has been reported after the iterative administration of Gd-based contrast agents (GBCAs) even in patients with normal renal function; the globus pallidus and dentate nucleus are GBCA-related hyperintensity areas on T1WIs.[1-5] The signal intensity (SI) and residual Gd in these brain regions reflect the total dose of GBCAs administered over time.[1-3,6,7] As free Gd is cytotoxic, it is delivered in chelated form.[8] High SI on T1WIs varies with the chelate type of previously administered GBCAs and is correlated with the administration of linear but not macrocyclic chelate GBCAs because linear-type is more unstable than macrocyclic-type GBCAs.[4,9-11] High SI in the cerebral cortices on T1WIs of patients with previous administrations of GBCAs has not been reported. We document T1 shortening of the cerebral cortices in a patient who had undergone multiple GBCA-enhanced studies.

Case Report

This 34-year-old man presented with bilateral hearing loss at the age of 14. He harbored bilateral acoustic and spinal schwannomas and was diagnosed with neurofibromatosis type 2. At the age of 33 he was also diagnosed with meningioma and he underwent many surgical and radiotherapy (e.g., r-knife, cyber-knife) treatments. For pre- and post-treatment evaluations he had undergone multiple contrast-enhanced MR studies using GBCAs. He manifested no renal dysfunction. We suspect that contrast-enhanced MR examinations had been performed before 2003, but we were not able to obtain the information about the administration of GBCAs before 2003 because of no records remained for that. We confirmed that between 2003 and 2014, 86 GBCA-enhanced studies had been performed; 59 were gadopentetate dimeglumine (Magnevist; Bayer Yakuhin, Osaka, Japan)-, 24 gadoterate meglumine (Magnescope; Terumo, Tokyo, Japan)-, and 3 gadoteridol (ProHance; Eisai, Tokyo, Japan)-enhanced. Most often the linear-type ionic contrast agent gadopentetate dimeglumine had been administered. MRI scans acquired in 2003 were the earliest images available to us. In 2003, the studies were performed on a Philips (Marconi) MAGNEX Eclipse 1.5T scanner (T1WI, TR/TE = 500 ms /11.4 ms; slice thickness = 5 mm; matrix = 256 × 256; field-of-view (FOV) = 230 mm). Thereafter a GE SIGNA EXCITE Echo Speed Plus 1.5T scanner was used (T1WI, TR/TE = 450 ms /12 ms; slice thickness = 5 mm; matrix = 256 × 256; FOV = 230 mm). Although the scanners were different, the imaging parameters were similar. On the T1WIs acquired in 2003, we observed high SI in the globus pallidus, dentate nucleus, and pulvinar of thalamus (Fig. 1). On T1WI scans performed in 2014, we noticed prominent high SI not only in the globus pallidus, dentate nucleus, and pulvinar of thalamus, but also in the cortices of the pre- and post-central gyri and around the calcarine sulcus (Figs. 2 and 3).
Fig 1.

T1-weighted images obtained in 2003. (a) T1-weighted image shows high-signal intensity in the dentate nucleus (arrows) (b) T1-weighted image shows high-signal intensity in the globus pallidus and pulvinar of thalamus (arrows).

Fig 2.

T1-weighted images at the level of the central sulcus. High-signal intensity can be seen more clearly on the 2014- (b) than the 2003 image (a) (arrows).

Fig 3.

T1-weighted images at the level of the calcarine sulcus. High-signal intensity is more apparent on the 2014- (b) than the 2003 (a) image (arrows).

Discussion

High SI on T1WIs of the globus pallidus, dentate nucleus, and pulvinar of thalamus secondary to Gd deposition has been documented.[1-7] However, our search of the literature found no reports of high SI attributable to Gd deposits in the cerebral cortices on T1WIs. Ours is the first documentation of high SI in the cortices of the pre- and post-central gyri and around the calcarine sulcus on T1WI scans of patients who had undergone multiple GBCA-enhanced imaging studies. Although the mechanism(s) underlying Gd deposition in the brain is not fully understood, processes involved in the deposition of Gd in brain tissue have been suggested. Dechelation and transmetallation can give rise to a dissociation between Gd and its chelate.[12] The possibility of the release of free Gd from the chelate in any GBCAs cannot be ruled out. Transmetallation, the exchange of Gd for other endogenous metal ions like iron, calcium, copper, and zinc that compete with Gd for chelation is also a possibility. The presence of free Gd in brain tissue suggests that Gd may be able to cross the blood brain barrier (BBB) even in the absence of evidence that the BBB has been compromised.[3] As the passive transport of Gd is unlikely, some biological mechanism(s) such as metal transporter(s) may be involved.[7,13] While iron circulating in the blood outside the central nervous system cannot cross the BBB directly, iron can be transferred across the BBB by several pathways. The probably most common is through transferrin receptors on brain endothelial cells; the receptors bind iron circulating in the form of transferrin. The transferrin receptor-bound complex then enters the brain by endocytosis. Other transporter systems such as the divalent metal transporter and the lactoferrin receptor may be involved in the delivery of iron across the BBB.[14,15] The high SI in the deep gray matter and cerebral cortices on T1WI scans of our patient corresponded with areas identified in histochemical studies as areas with normal iron-deposition predilection.[16,17] Spatz[16] who reported a macroscopic, qualitative histochemical study of brain iron, divided the brain regions into four groups according to their iron content. The first, most intensely stained group was comprised of the globus pallidus and the substantia nigra. The second, consistently but less strongly stained group included the red nucleus, putamen, and the caudate- and dentate nucleus. The third group contained the cerebral and cerebellar cortex, the anterior thalamic nucleus, the mammillary body, and the tectum of the mid-brain; it was stained variably and considerably weaker. The regions in the fourth group showed no histochemical iron staining; they were the medulla oblongata, the gray matter of the spinal cord, and the white matter of the brain and spinal cord. Hallgren and Sourander[17] who studied the quantitative effect of age on non-heme iron in the human brain found that the iron content in the cerebral cortices increased with age; in the older study population the motor cortex (pre-central gyrus) had a mean iron content of approximately 5.0 mg/100 g, closely followed by the visual cortex (occipital cortex), the sensory cortex (post-central gyrus), and the rest of the parietal cortex. The temporal and pre-frontal cortices showed the lowest iron content (mean nearly 3.0 mg/100 g). The amount of iron deposition was highest in the motor-, followed by the visual- and the sensory cortex. They also detected nonheme iron in the globus pallidus, dentate nucleus, and thalamus; its content was higher in the globus pallidus (21–30 mg/100 g). These iron depositions in the deep gray matter and specific cerebral cortices were also observed on conventional spin-echo T2WI but not on fast spin-echo T2WI.[18-20] On the other hand, no abnormal SI was observed in the motor and visual cortices on T1WI scans of healthy, even elderly individuals.[19,20] We think that the T1 shortening of the cerebral cortices we observed in our patient was due to excessive Gd accumulation in the cortices after the multiple administrations of GBCAs. This case report has some limitations. We did not obtain the evidence of histochemically proven Gd deposition in the specific cerebral cortices. Therefore, we are not able to make a definitive statement. In addition, this patient had neurofibromatosis type 2 and underwent many surgical and radiotherapy treatments. Although these effects might have affected the MRI findings of the cerebral cortices, it is strongly suspected that Gd accumulation in the cortices caused the T1 shortening of the cerebral cortices. In conclusion, we report a patient with T1 shortening in certain cerebral cortices after he had undergone more than 80 administrations of GBCAs. Based on our findings, we speculate that Gd deposition in the brain may be associated with the iron metabolism.
  19 in total

1.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent.

Authors:  Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Radiology       Date:  2015-04-06       Impact factor: 11.105

2.  Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation.

Authors:  Yuri Errante; Vincenzo Cirimele; Carlo Augusto Mallio; Vincenzo Di Lazzaro; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi
Journal:  Invest Radiol       Date:  2014-10       Impact factor: 6.016

3.  Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T.

Authors:  S Aoki; Y Okada; K Nishimura; A J Barkovich; B O Kjos; R C Brasch; D Norman
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

4.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

5.  T2 shortening in the visual cortex: effect of aging and cerebrovascular disease.

Authors:  Y Korogi; T Hirai; Y Komohara; T Okuda; I Ikushima; M Kitajima; Y Shigematu; T Sugahara; M Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  1997-04       Impact factor: 3.825

Review 6.  Hereditary causes of disturbed iron homeostasis in the central nervous system.

Authors:  Prem Ponka
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

Review 7.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

8.  High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images: Evaluation of the Macrocyclic Gadolinium-Based Contrast Agent Gadobutrol.

Authors:  Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Johanna Hepp; Philipp Kickingereder; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Invest Radiol       Date:  2015-12       Impact factor: 6.016

Review 9.  Brain gadolinium deposition after administration of gadolinium-based contrast agents.

Authors:  Tomonori Kanda; Hiroshi Oba; Keiko Toyoda; Kazuhiro Kitajima; Shigeru Furui
Journal:  Jpn J Radiol       Date:  2015-11-25       Impact factor: 2.374

10.  T2 shortening in the motor cortex: effect of aging and cerebrovascular diseases.

Authors:  T Hirai; Y Korogi; Y Sakamoto; S Hamatake; I Ikushima; M Takahashi
Journal:  Radiology       Date:  1996-06       Impact factor: 11.105

View more
  9 in total

Review 1.  Distribution and chemical forms of gadolinium in the brain: a review.

Authors:  Tomonori Kanda; Yudai Nakai; Akifumi Hagiwara; Hiroshi Oba; Keiko Toyoda; Shigeru Furui
Journal:  Br J Radiol       Date:  2017-09-28       Impact factor: 3.039

Review 2.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

Review 3.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 4.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

Review 5.  Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.

Authors:  Joel Garcia; Stephen Z Liu; Angelique Y Louie
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-11-28       Impact factor: 4.226

6.  Longitudinal Assessment of Dentate Nuclei Relaxometry during Massive Gadobutrol Exposure.

Authors:  Enrico Tedeschi; Sirio Cocozza; Pasquale Borrelli; Lorenzo Ugga; Vincenzo Brescia Morra; Giuseppe Palma
Journal:  Magn Reson Med Sci       Date:  2017-03-27       Impact factor: 2.471

Review 7.  Gadolinium Deposition in the Brain: Current Updates.

Authors:  Jin Woo Choi; Won-Jin Moon
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

8.  Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents.

Authors:  Henning Richter; Patrick Bücker; Calvin Dunker; Uwe Karst; Patrick Robert Kircher
Journal:  PLoS One       Date:  2020-02-03       Impact factor: 3.240

Review 9.  Retention of Gadolinium in Brain Parenchyma: Pathways for Speciation, Access, and Distribution. A Critical Review.

Authors:  Marlène Rasschaert; Roy O Weller; Josef A Schroeder; Christoph Brochhausen; Jean-Marc Idée
Journal:  J Magn Reson Imaging       Date:  2020-04-04       Impact factor: 4.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.